SCM
CRSP icon

Stevens Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Stevens Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,585
Closed -$218K – 92
2019
Q4 		$218K Buy
+3,585
New +$196K 0.02% 516

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stevens Capital Management's CRSP Position: Q1 2020 in Review

Stevens Capital Management sold out of CRISPR Therapeutics (CRSP) in Q1 2020, closing a stake of 3,585 shares — an estimated $218K sold.

Stevens Capital Management first reported a position in CRSP in Q4 2019 and held it in 1 quarter. The position peaked at $218K in Q4 2019. 257 funds tracked by Wall St. Rank hold CRSP as of Q1 2020.

  • Stevens Capital Management reported no remaining CRISPR Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Stevens Capital Management sold 3,585 CRISPR Therapeutics shares in Q1 2020, an estimated $218K.
  • Stevens Capital Management first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 1 quarter.
  • Stevens Capital Management's CRISPR Therapeutics position peaked at $218K in Q4 2019.
  • 257 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2020.

Based on Stevens Capital Management's 13F filing for Q1 2020, filed 21 Apr 2020.